Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo.
Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo. The follow-on was approved by the FDA earlier this month.
According to Pfenex, the study included 102 untrained participants, 52 of whom were patients with osteoporosis and 50 of whom were caregivers. Of the 18 critical tasks assessed, patients using the follow-on had fewer user errors or the same number of errors for 12 (67%) of those tasks. Among caregivers, there were equal numbers of user errors or fewer errors for 15 (83%) of the tasks.
No error difference, in either of the user groups, exceeded the prespecified maximum allowable difference.
In a statement, Pfenex’s chief executive officer, Eef Schimmelpennink, said that the outcome of the study “demonstrates noninferiority between the user interfaces of our product and Forteo,” and that the company will present the data to the FDA as part of a package that the regulator will review to evaluate therapeutic equivalence of the product with its reference.
Because PF708 was approved under the 505(b)(2) approval pathway instead of the biosimilar approval pathway, Pfenex can seek pharmacy-level substitutability for the product without having to undertake the kinds of extra clinical studies that a biosimilar would be subject to if seeking an interchangeable designation; because it is a follow-on and not a biosimilar, PF708 will be evaluated for a determination therapeutic equivalence rather than an interchangeable designation.
When the follow-on was first approved, Schimmelpennink noted that, in order to optimize patient and payer impact, Pfenex’s partner Alvogen will launch PF708 once the FDA has made its decision on therapeutic equivalence for the product.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.